Home Cart Sign in  
Chemical Structure| 232931-57-6 Chemical Structure| 232931-57-6

Structure of SJG-136
CAS No.: 232931-57-6

Chemical Structure| 232931-57-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SJG-136 is a rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity.

Synonyms: NSC-694501

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SJG-136

CAS No. :232931-57-6
Formula : C31H32N4O6
M.W : 556.61
SMILES Code : O=C1C2=CC(OC)=C(OCCCOC3=C(OC)C=C4C(N=C[C@@](CC(C5)=C)([H])N5C4=O)=C3)C=C2N=C[C@@]6([H])N1CC(C6)=C
Synonyms :
NSC-694501
MDL No. :MFCD19443671
InChI Key :RWZVMMQNDHPRQD-SFTDATJTSA-N
Pubchem ID :393111

Safety of SJG-136

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of SJG-136

DNA

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00121290 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Completed - United States, Tennessee ... More >> Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 Less <<
NCT00301769 Adult Acute Myeloid Leukemia W... More >>ith 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Blastic Phase Chronic Myelogenous Leukemia de Novo Myelodysplastic Syndromes Previously Treated Myelodysplastic Syndromes Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Refractory Chronic Lymphocytic Leukemia Relapsing Chronic Myelogenous Leukemia Secondary Acute Myeloid Leukemia Secondary Myelodysplastic Syndromes Less << Phase 1 Terminated - United States, Texas ... More >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01200797 - Terminated(Slow accrual was th... More >>e reason for study termination.) Less << - -
NCT00103220 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Completed - United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT01200797 Recurrent Fallopian Tube Cance... More >>r Recurrent Ovarian Epithelial Cancer Recurrent Primary Peritoneal Cavity Cancer Less << Phase 2 Terminated(Slow accrual was th... More >>e reason for study termination.) Less << - United States, Connecticut ... More >> Hartford Hospital Hartford, Connecticut, United States, 06102 Oncology Associates PC Hartford, Connecticut, United States, 06106 United States, Florida H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, New Jersey Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Virginia Virginia Commonwealth University Richmond, Virginia, United States, 23298 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.80mL

0.36mL

0.18mL

8.98mL

1.80mL

0.90mL

17.97mL

3.59mL

1.80mL

References

[1]Reid JM, Buhrow SA, et al. Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats. Cancer Chemother Pharmacol. 2011 Sep;68(3):777-86.

[2]Hartley JA, Spanswick VJ, et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res. 2004 Sep 15;64(18):6693-9.

[3]Gregson SJ, Howard PW, Hartley JA, Brooks NA, Adams LJ, Jenkins TC, Kelland LR, Thurston DE. Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. J Med Chem. 2001 Mar 1;44(5):737-48. doi: 10.1021/jm001064n. PMID: 11262084.

[4]Hartley JA, Spanswick VJ, Brooks N, Clingen PH, McHugh PJ, Hochhauser D, Pedley RB, Kelland LR, Alley MC, Schultz R, Hollingshead MG, Schweikart KM, Tomaszewski JE, Sausville EA, Gregson SJ, Howard PW, Thurston DE. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res. 2004 Sep 15;64(18):6693-9. doi: 10.1158/0008-5472.CAN-03-2941. PMID: 15374986.

[5]Mellinas-Gomez M, Spanswick VJ, Paredes-Moscosso SR, Robson M, Pedley RB, Thurston DE, Baines SJ, Stell A, Hartley JA. Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours. BMC Vet Res. 2015 Aug 19;11:215. doi: 10.1186/s12917-015-0534-2. PMID: 26282406; PMCID: PMC4539724.

[6]Pepper CJ, Hambly RM, Fegan CD, Delavault P, Thurston DE. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill. Cancer Res. 2004 Sep 15;64(18):6750-5. doi: 10.1158/0008-5472.CAN-04-1713. PMID: 15374993.

 

Historical Records

Categories